AbbVie Inc. (ABBV)

NYSEHealthcare

$208.28
-$6.69 (-3.1%)
Market closed

April 2, 2026 at 20:00 UTC

Interactive Chart

ABBV
1H
3H
6H
12H
1D
1W
1M
3M
6M
1Y
2Y
5Y
All

16:51:14 UTC

About AbbVie Inc.

Name
AbbVie Inc.
CEO
Scott T. Reents
Industry
Healthcare
Year Founded
2011
Employees
55,000

AbbVie Inc. is a biopharmaceutical company that researches, develops, and markets therapies across immunology, oncology, neuroscience, and other therapeutic areas. The company is known for both specialty medicines and a pipeline of investigational drugs designed to address chronic and complex diseases. Its research strategy emphasizes biologics, small molecules, and targeted therapies supported by clinical trials and global partnerships. With worldwide operations, AbbVie integrates advanced science with commercial scale to deliver healthcare solutions. Positioned within the healthcare sector, the company reflects the growing role of biotechnology in modern medicine.

Analyst Ratings

Consensus Recommendation
Analyst consensus: 4 Buy, 9 Hold, 11 Sell
Buy4
Hold9
Sell11

Fundamentals & Financials

Revenue (TTM)
$61.1B
Net Income (TTM)
$4.2B
EPS (TTM)
$2.37
ROA (TTM)
3.15%
Current Ratio
0.67
Dividend Yield
0.097%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

ItemQ4 2025
Revenue$16,618M
Cost of Sales$2,656M
Gross Profit$13,962M
Operating Income$5,809M
Net Income$1,816M
EPS$1.02

Technical Indicators

AbbVie Inc.'s Technical Indicators Summary

ABBV's technicals lean bearish as price sits under several medium-term averages and volume dynamics lack support. Short-term averages are constructive, but the broader moving-average structure shows resistance and VWAP plus classic pivots are above the market, adding overhead pressure. Momentum readings are mixed and ADX is subdued, while OBV is negative and volatility is moderate, implying limited bullish conviction. Technical takeaway: Bearish — medium-term moving-average resistance and weak volume favor a cautious, negative bias.

Buy
4 signals
Neutral
9 signals
Sell
11 signals
Overall: Bearish46% Bearish signals
IndicatorValue
RSI (14)
46.78
Stochastic %K (14, 3, 3)
49.54
CCI (20)
-6.21
WPR (14)
-51.06
Momentum (10)
6.59
MFI
36.87
MACD Level (12, 26)
-3.58
Bollinger Bands
$198.00 - $235.39
ATR (14)
$5.72 (2.66%)
ADX (14)
21.93
OBV
8,684,668
VWAP
$215.69
Classic Pivot Point
$217.17
Fibonacci Pivot Point
$217.17
Simple Moving Averages
$209.47 - $223.93(5 indicators)
Exponential Moving Averages
$212.60 - $220.54(5 indicators)
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

End-of-day pricing shows ABBV still under yesterday’s 214.98, with the -2.86% gap down leaving it at 208.84. End-of-day sector performance was slightly negative (-0.62%), mildly offsetting stock-specific strength. ABBV slides as proposed US tariffs on branded drugs threaten margins and growth prospects.

Price Change

from $208.29 close

+$0.53

Trading Volume

Below avg (8.5M)

5M

vs S&P 500 Today

Strong Underperformance

-6.25%

52-Week Position

Mid-range

55.3%

Updated: April 3, 2026 at 20:09 UTC

Quote Summary

OpenPrevious Close
$218.37$217.65
Day Range52 Week Range
$213.78 - $220.45$164.39 - $244.81
VolumeAvg. Volume
3.3M7.3M
Market CapP/E Ratio
$378.8B90.8